Beyond expectations: investigating nilotinib’s potential in attenuating neurodegeneration in alzheimer’s disease

Simple item page
dc.contributor.authorTocci, Darcy
dc.contributor.authorFogel, Maiah
dc.contributor.authorGupta, Vanya
dc.contributor.authorKim, Peter
dc.contributor.authorLatimer, Jean
dc.contributor.authorAdlimoghaddam, Aida
dc.contributor.authorRobison, Lisa S.
dc.contributor.authorAlbensi, Benedict C.
dc.date.accessioned2025-04-11T14:59:26Z
dc.date.available2025-04-11T14:59:26Z
dc.date.issued2025-03-15
dc.date.updated2025-04-01T05:04:35Z
dc.description.abstractAbstract Neurodegenerative diseases, such as Alzheimer’s disease (AD), pose a formidable global challenge. While therapeutic options are available, their limitations are significant, necessitating the development of innovative treatment approaches. Here, we highlight the importance of repurposing drugs and discuss the future of drug treatments for AD. We review the potential of tyrosine kinase inhibitors (TKI) for mitigating AD pathology and symptoms, as well as neurodegenerative processes more broadly. We focus on nilotinib, a selective BCR-ABL tyrosine kinase inhibitor, which has unique mechanisms of action involving the modulation of cell responses and removal of toxic proteins associated with AD pathogenesis. Encouraging studies have demonstrated its efficacy, calling for further investigation through clinical trials to assess its potential in various neurodegenerative conditions. However, despite these promising preclinical findings, no clinical studies have yet conclusively demonstrated its efficacy in treating AD. Considering the future directions in AD research, personalized medicine approaches hold promise by incorporating patient-specific factors, including sex and gender differences, to tailor nilotinib treatment for improved efficacy and safety profiles.
dc.identifier.citationAlzheimer's Research & Therapy. 2025 Mar 15;17(1):60
dc.identifier.doi10.1186/s13195-025-01706-w
dc.identifier.urihttp://hdl.handle.net/1993/39010
dc.language.isoeng
dc.language.rfc3066en
dc.publisherBMC
dc.rights.holderThe Author(s)
dc.subjectRepurposed
dc.subjectAlzheimer disease
dc.subjectNeurodegeneration
dc.subjectAutophagy
dc.subjectMemory
dc.subjectProtein aggregates
dc.titleBeyond expectations: investigating nilotinib’s potential in attenuating neurodegeneration in alzheimer’s disease
dc.typereview article
local.author.affiliationRady Faculty of Health Sciences::Max Rady College of Medicine::Department of Pharmacology and Therapeutics
oaire.citation.startPage60
oaire.citation.titleAlzheimer's Research & Therapy
oaire.citation.volume17
project.funder.identifierhttps://doi.org/10.13039/501100000024
project.funder.nameCanadian Institutes of Health Research
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13195_2025_Article_1706.pdf
Size:
1.64 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
770 B
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship